Oran is the first child in the UK to participate in a successful DBS clinical trial for pediatric epilepsy.
Oran's seizures started when he was three years old and had not had a single day without a seizure until the trial.
The device targets the thalamus, a crucial relay station for neuronal information, and blocks electrical pathways to stop seizures from spreading.
In a groundbreaking development, the first child in the UK, identified as Oran, has undergone a successful deep brain stimulation (DBS) treatment for epilepsy. This innovative therapy targets the thalamus, a crucial hub for electrical signals in the brain that is believed to block electrical pathways and prevent seizures from spreading. Oran's condition had been severe since his early childhood, with no day without a seizure until this trial.
The CADET pilot clinical trial at Great Ormond Street Hospital (GOSH) marks the beginning of a new era in epilepsy treatment. The rechargeable DBS device is attached to electrodes deep in the brain and is designed to reduce seizure activity, making it a significant improvement over previous devices that required surgery for replacement every three to five years.
Oran's story began when he was just three years old, with his first seizure. His condition worsened over the years, leaving him unable to live a normal childhood due to frequent and debilitating seizures. However, after undergoing the DBS procedure in October 2023 at GOSH, Oran's life has dramatically changed for the better.
The trial will recruit three more children with Lennox-Gastaut syndrome before expanding to a full trial involving 22 patients. This new treatment holds great promise for improving the lives of many children suffering from severe epilepsy.
Key Facts:
Oran is the first child in the UK to participate in a successful DBS clinical trial for pediatric epilepsy.
The device targets the thalamus, a crucial relay station for neuronal information, and blocks electrical pathways to stop seizures from spreading.
Oran's seizures started when he was three years old and had not had a single day without a seizure until the trial.
Further research will recruit three additional patients with Lennox-Gastaut syndrome before 22 patients take part in the full trial, which is funded by GOSH Charity and LifeArc.
Oran is the first child in the UK to participate in the CADET pilot clinical trial for this type of treatment for pediatric epilepsy.
The device targets the thalamus, which is a hub for electrical signals in the brain, and it is hoped that it will block electrical pathways to stop seizures from spreading.
Oran's seizures started when he was three years old and had not had a single day without a seizure until the trial.
Further research will recruit three additional patients with Lennox-Gastaut syndrome before 22 patients take part in the full trial, which is funded by GOSH Charity and LifeArc.
Oran is the first patient in the world to trial a new device fitted in his skull to control seizures
Oran suffered several daily seizures ranging from two dozen to hundreds before surgery
The neurostimulator, made by UK company Amber Therapeutics, sends electrical signals deep into Oran’s brain to block or disrupt abnormal signals causing seizures
Oran underwent surgery in October 2023 to insert electrodes deep into his brain and connect them to the neurostimulator
Three more children with Lennox-Gastaut syndrome will be fitted with the deep brain neurostimulator as part of the trial
Accuracy
The device targets the thalamus, which is a hub for electrical signals in the brain
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
No formal fallacies found. The author does not make any extreme or unsupported claims. However, there are a few instances of inflammatory rhetoric and appeals to authority which slightly reduce the score.
The neurostimulator, which sends electrical signals deep into his brain, has reduced Oran Knowlson's daytime seizures by 80%.
Oran is the first child in the UK to participate in the CADET pilot clinical trial for this type of treatment for pediatric epilepsy.
The device targets the thalamus, a hub for electrical signals in the brain, and it is hoped that it will block electrical pathways to stop seizures from spreading.
Oran's neurostimulator was implanted with two electrodes precisely reaching the thalamus, a crucial relay station for neuronal information.
The rechargeable DBS device is attached to electrodes deep in the brain and is designed to reduce seizure activity. It is mounted onto the skull, reducing the likelihood of leads breaking or eroding as the child grows.
Unlike other DBS devices, this one can be recharged through wearable headphones and does not require surgery to replace it every three to five years.
Oran is the first patient in the UK to have a deep brain stimulation (DBS) device implanted to treat his condition.
Oran's daytime seizures have reduced by 80% and his overall seizure frequency and severity have dramatically decreased thanks to the device.
The CADET pilot trial will recruit three additional patients with Lennox-Gastaut syndrome before a full trial involving 22 patients takes place.
Unlike other DBS devices, this one can be recharged through wearable headphones and does not require surgery to replace it every three to five years.
The device targets the thalamus, a hub for electrical signals in the brain, in an attempt to block electrical pathways and stop seizures from spreading.
Oran's story: Before his epilepsy worsened, he had a mutation in the SCNIB gene, which also affected his family members who now have control of their seizures. However, Oran’s epilepsy became more severe and often required resuscitation.
Since receiving the DBS device, Oran’s daytime seizures have significantly reduced in frequency and severity. His overall quality of life has improved as he is more engaged and can better express himself.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The article contains an appeal to authority with the quotes from Martin Tisdall and Tim Denison. However, the article does not contain any logical fallacies that would significantly impact the validity of the information presented.
Martin Tisdell: “Every single day we see the life-threatening and life-limiting impacts of uncontrollable epilepsy. It can make school, hobbies or even just watching a favourite TV show utterly impossible.”
Tim Denison: “Our mission is to design pioneering research systems for exploring the treatment of intractable health conditions such as paediatric epilepsy. Oran is the first child in the world to receive this device and we are extremely pleased that it has had such a positive benefit for him and his family.”
